Phase IIa study of TAR-0520 gel to prevent capecitabine-induced hand-foot syndrome

Phase 2, single-arm trial of brimonidine in Erythrodysesthesia syndrome (PPE), sponsored by Tarian Pharma. Primary endpoint: Incidence of Adverse Events, Adverse Events of Special Interest and Serious Adverse Events. Planned start Feb 2026; status: authorised.